Skip to content

Replimune Group REPL Net Change in Cash

Net Change in Cash at other companies

Amgen logo
AmgenAMGN
$2.91B+192%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$153.1M-125%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$37.44M-41.4%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
CG Oncology logo
CG OncologyCGON
$1.21M+101%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$26.55M-1,068%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's net change in cash?
Replimune Group (REPL) reported net change in cash of $20.65M in Q4 2025.
How has Replimune Group's net change in cash changed year-over-year?
Replimune Group's net change in cash decreased by 64.8% year-over-year, from $58.75M to $20.65M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.